ONCR Stock Price, Oncorus Inc Quote, Chart

Market Summary

USD0.13

Market Closed

ONCR Stock Price

View Fullscreen

ONCR RSI Chart

ONCR Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.04

Price/Free Cashflow

-0.05

ONCR Price/Earnings (Trailing)

ONCR Profitability

Free Cashflow Yield

-2.2K%

ONCR Fundamentals

ONCR Earnings

Breaking Down ONCR Revenue

Last 7 days

1200%

Last 30 days

550%

Trailing 12 Months

-54.1%

How does ONCR drawdown profile look like?

ONCR Financial Health

ONCR Investor Care

Tracking the Latest Insider Buys and Sells of Oncorus Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 30, 2022	flynn james e	sold	-50,079	0.27	-185,478	-
Dec 30, 2022	flynn james e	sold	-12,328	0.27	-45,660	-
Dec 29, 2022	flynn james e	sold	-12,119	0.26	-46,614	-
Dec 29, 2022	flynn james e	sold	-49,224	0.26	-189,324	-
Dec 29, 2022	flynn james e	sold	-49,223	0.26	-189,321	-
Dec 28, 2022	flynn james e	sold	-18,567	0.25	-74,271	-
Dec 28, 2022	flynn james e	sold	-4,572	0.25	-18,288	-
Dec 27, 2022	flynn james e	sold	-1,926	0.27	-7,136	-

Which funds bought or sold ONCR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 08, 2024	Your Advocates Ltd., LLP	sold off	-100	-3.00	-	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	4,000	4,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	added	302	27,000	99,000	-%
Feb 15, 2022	NEXT Financial Group, Inc	new	-	40,000	40,000	-%
Nov 15, 2021	Marshall Wace North America L.P.	unchanged	-	-1,383,000	2,894,000	0.01%
Jul 28, 2021	Hoover Financial Advisors, Inc.	sold off	-100	-7,000	-	-%

Are Funds Buying or Selling ONCR?

Are funds buying ONCR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ONCR

No. of Funds

Unveiling Oncorus Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	citadel advisors llc	7.2%	6	SC 13G/A
Feb 13, 2023	chi advisors llc	9.11%	2,367,436	SC 13G/A
Feb 02, 2023	arkin moshe	4.11%	1,067,093	SC 13G/A
Jan 19, 2023	flynn james e	1.74%	451,940	SC 13D/A
Jan 17, 2023	flynn james e	2.71%	704,097	SC 13D/A
Jan 03, 2023	flynn james e	4.35%	1,129,095	SC 13D/A
Dec 22, 2022	flynn james e	5.15%	1,338,669	SC 13D/A
Nov 01, 2022	k2 healthventures equity trust llc	9.1%	2,593,767	SC 13G
Jul 08, 2022	blackrock inc.	1.1%	278,740	SC 13G
Feb 15, 2022	perceptive advisors llc	3.9%	999,812	SC 13G/A

Peers (Alternatives to Oncorus Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	3.52%	-17.31%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-3.68%	-28.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-7.53%	-16.73%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-8.64%	-30.91%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-24.84%	-46.72%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-17.14%	78.66%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-20.91%	-36.67%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	-9.41%	-43.91%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-5.61%	336.79%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-17.51%	25.55%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-57.88%	56.88%	-0.24	2.14	-13.45%	66.37%

Oncorus Inc News

Latest updates

Oncorus Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-24.6%	110	146	164	183	177	202	203	216	225	182	62.00	58.00	55.00	51.00	26.00
Current Assets	-27.8%	47.00	65.00	83.00	103	103	129	148	163	176	133	56.00	-	-	46.00	21.00
Cash Equivalents	-17.5%	21.00	26.00	42.00	85.00	76.00	104	146	160	173	133	54.00	29.00	36.00	45.00	20.00
Net PPE	-21.4%	35.00	44.00	43.00	36.00	29.00	23.00	14.00	9.00	5.00	4.00	5.00	-	-	4.00	4.00
Liabilities	-7.6%	79.00	85.00	84.00	85.00	62.00	72.00	55.00	53.00	49.00	48.00	6.00	7.00	8.00	8.00	5.00
Current Liabilities	-16.4%	31.00	37.00	17.00	16.00	12.00	21.00	12.00	11.00	7.00	6.00	5.00	-	-	5.00	3.00
LT Debt, Non Current	-	-	-	19.00	19.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-48.6%	31.00	61.00	80.00	98.00	114	130	148	163	176	135	-	-	-	-	-
Retained Earnings	-11.4%	-302	-272	-251	-231	-212	-194	-174	-158	-142	-129	-118	-	-	-74.30	-40.98
Additional Paid-In Capital	0.4%	334	333	331	330	327	325	323	321	319	264	-	-	-	-	1.00
Shares Outstanding	0%	26.00	26.00	26.00	26.00	26.00	26.00	25.00	26.00	24.00	23.00	1.00	1.00	-	1.00	-
Float	-	-	-	-	26.00	-	-	-	243	-	467	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-23.4%	-17,447	-14,140	-10,854	-13,257	-23,437	-18,438	-9,848	-11,159	-10,379	-11,180	-10,004	-6,933	-8,690	-	-	-
Share Based Compensation	4.0%	1,467	1,411	1,640	2,180	1,980	1,856	1,889	1,656	1,172	779	340	316	303	-	-	-
Cashflow From Investing	841.1%	12,955	-1,748	-32,375	2,983	-1,868	-26,035	-4,518	-1,792	-385	-42.00	-267	-514	-233	-	-	-
Cashflow From Financing	-100.0%	-	29.00	-	19,562	62.00	182	49.00	249	53,081	90,385	35,369	-	5.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ONCR Income Statement

2023-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 10,630	$ 12,469
General and administrative	4,499	5,349
Total operating expenses	15,129	17,818
Impairment loss	(14,575)	0
Loss from operations	(29,704)	(17,818)
Other (expense) income:
Other expense	0	(38)
Interest (expense) income	(1,195)	76
Total other (expense) income, net	(1,195)	38
Net loss	(30,899)	(17,780)
Net unrealized loss on investments	(28)	(26)
Comprehensive loss	$ (30,927)	$ (17,806)
Net loss per share - basic	$ (1.18)	$ (0.69)
Net loss per share - diluted	$ (1.18)	$ (0.69)
Weighted-average number of common shares outstanding - basic	26,095	25,865
Weighted-average number of common shares outstanding - diluted	26,095	25,865

ONCR Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,217	$ 25,709
Investments	23,765	36,487
Prepaid expenses and other current assets	1,688	2,422
Total current assets	46,670	64,618
Property and equipment, net	34,852	44,360
Right-of-use asset	24,214	32,560
Restricted cash	3,437	3,437
Other assets	580	611
Total assets	109,753	145,586
Current liabilities:
Accounts payable	2,760	5,694
Accrued expenses and other current liabilities	6,623	10,948
Lease liability - current portion	1,187	1,129
Term loan, net of debt discount	20,538	19,436
Total current liabilities	31,108	37,207
Lease liability - net of current portion	47,524	47,854
Total liabilities	78,632	85,061
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized - 10,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding - no shares at March 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; authorized - 100,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding - 26,095 shares at March 31, 2023 and December 31, 2022	3	3
Additional paid-in capital	334,050	332,583
Accumulated other comprehensive loss	(24)	(52)
Accumulated deficit	(302,908)	(272,009)
Total stockholders’ equity	31,121	60,525
Total liabilities and stockholders’ equity	$ 109,753	$ 145,586

About Oncorus Inc

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

CEO	Mr. Craig R. Jalbert CIRA
WEBSITE	oncorus.com
INDUSTRY	Biotechnology
EMPLOYEES	64

Oncorus Inc Frequently Asked Questions

What is the ticker symbol for Oncorus Inc? What does ONCR stand for in stocks?

ONCR is the stock ticker symbol of Oncorus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncorus Inc (ONCR)?

As of Fri Dec 29 2023, market cap of Oncorus Inc is 3.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONCR stock?

You can check ONCR's fair value in chart for subscribers.

What is the fair value of ONCR stock?

You can check ONCR's fair value in chart for subscribers. The fair value of Oncorus Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oncorus Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oncorus Inc a good stock to buy?

The fair value guage provides a quick view whether ONCR is over valued or under valued. Whether Oncorus Inc is cheap or expensive depends on the assumptions which impact Oncorus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONCR.